Gain Therapeutics, Inc. (GANX) Earnings History
Annual and quarterly earnings data from 2018 to 2024
Loading earnings history...
GANX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
GANX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | 100.0% | -40328.3% | -40354.3% |
| 2022 | -6114.6% | -13402.5% | -13262.0% |
| 2021 | -5249.3% | -10323.6% | -10371.7% |
| 2020 | 100.0% | -12047.5% | -12387.7% |
Download Data
Export GANX earnings history in CSV or JSON format
Free sign-in required to download data
Gain Therapeutics, Inc. (GANX) Earnings Overview
As of May 8, 2026, Gain Therapeutics, Inc. (GANX) reported trailing twelve-month net income of -$19M, reflecting +48.0% year-over-year growth. The company earned $-0.55 per diluted share over the past four quarters.
Looking at the long-term picture, GANX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2018.
Gain Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ACMR ($94M net income, 10.4% margin), RARE (-$609M net income, -85.4% margin), GANX has comparable earnings metrics. Compare GANX vs PRAX →
GANX Earnings vs Peers
Earnings metrics vs comparable public companies
GANX Historical Earnings Data (2018–2024)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$20M | +8.3% | -$20M | $-0.89 | - | - |
| 2023 | -$22M | -26.6% | -$22M | $-1.71 | -40354.3% | -40328.3% |
| 2022 | -$18M | -26.6% | -$18M | $-1.48 | -13262.0% | -13402.5% |
| 2021 | -$14M | -288.3% | -$14M | $-1.37 | -10371.7% | -10323.6% |
| 2020 | -$4M | -63.1% | -$3M | $-0.30 | -12387.7% | -12047.5% |
| 2019 | -$2M | -98.4% | -$2M | $-0.26 | -5310.9% | -5084.9% |
| 2018 | -$1M | - | -$1M | $-0.19 | -5364.4% | -4989.7% |
See GANX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GANX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GANX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGANX — Frequently Asked Questions
Quick answers to the most common questions about buying GANX stock.
Is GANX growing earnings?
GANX EPS is $-0.55, with earnings growth accelerating to +48.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-19M.
What are GANX's profit margins?
Gain Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are GANX's earnings?
GANX earnings data spans 2018-2024. The accelerating earnings trend is +48.0% YoY. Historical data enables comparison across business cycles.